Probiotics for Gastrointestinal Health

Introduction to Probiotics

• Probiotics, including Saccharomyces boulardii, act as beneficial microorganisms that help restore normal intestinal flora, competing with pathogenic organisms for attachment sites and nutrients, reducing inflammatory response, and producing enzymes to neutralize bacterial toxins 1
• Saccharomyces boulardii stimulates the production of secretory IgA and other components of the immune system, strengthening intestinal barrier function 1

Prevention of Antibiotic-Associated Diarrhea

• The American Gastroenterological Association (AGA) and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) suggest using specific probiotics, including Saccharomyces boulardii and Lactobacillus rhamnosus GG, for prevention of antibiotic-associated diarrhea 2, 3
• Evidence suggests S. boulardii may increase cessation of diarrhea (RR, 1.33; 95% CI, 1.02-1.74) and decrease recurrence (RR, 0.59; 95% CI, 0.35-0.98) 2
• Probiotics, including Saccharomyces boulardii, may reduce the duration of diarrhea by approximately 21.91 hours (95% CI: 16.17-27.64) and decrease the risk of prolonged diarrhea (>3 days) (RR 0.62; 95% CI: 0.56-0.70) and (>4 days) (RR 0.50; 95% CI: 0.40-0.62) 1

Effective Probiotic Strains

• Lactobacillus rhamnosus GG has strong evidence for prevention of nosocomial diarrhea and treatment of acute gastroenteritis 4, 3
• Saccharomyces boulardii is effective for antibiotic-associated diarrhea and C. difficile infection 4, 2
• Lactobacillus reuteri is effective for acute gastroenteritis, especially in breastfed infants with colic 3
• Specific probiotic strains, such as Lactobacillus rhamnosus ATCC 53103 and Lactobacillus reuteri, may reduce the duration of diarrhea and the proportion of children with diarrhea >4 days in children with acute gastroenteritis 1

Special Considerations

• Lactobacillus rhamnosus ATCC 53103 may actually increase recurrence of C. difficile infection 2
• Probiotics should be used with caution in premature neonates, immunocompromised patients, critically ill patients, patients with central venous catheters, patients with cardiac valvular disease, and patients with short-gut syndrome 3
• Saccharomyces boulardii should be avoided in severely debilitated or immunocompromised patients, particularly those with central venous catheters, due to rare risk of fungemia 4
• Common side effects of Saccharomyces boulardii include mild rash, nausea, gas, flatulence, and abdominal bloating 4
• Probiotic use has a low adverse event rate (4% in probiotic groups vs 6% in control groups) 3, 5

Dosage and Administration

• The recommended dose of Saccharomyces boulardii is ≥10 billion CFU/day (approximately 1g daily or 3×10¹⁰ CFU/day) 1, 4, 6, 2
• High-dose probiotics (≥10 billion CFU/day) are more effective than low-dose options and should be taken 2 hours apart from antibiotics 4, 6, 2
• The following probiotic strains and dosages are recommended:

Adjunctive Therapy

• Probiotics may be considered as adjunctive therapy in specific cases of acute infectious diarrhea, particularly outside North America, with rehydration as the primary therapy 7
• Probiotics, including Saccharomyces boulardii and Lactobacillus rhamnosus GG, may have a role as adjunctive therapy in antibiotic-associated diarrhea, with moderate strength evidence and a weak recommendation from the Infectious Diseases Society of America 8, 2
• Multi-strain probiotics demonstrate better outcomes than single-strain options, and may be beneficial for hospital inpatients receiving antibiotics, pediatric patients, and those at higher risk of developing CDAD 4, 6, 9
• Probiotic use has been associated with a decreased recurrence of C. difficile infection when used with appropriate antibiotics, with specific strains reducing CDAD risk by 59% (RR 0.41; 95% CI, 0.22-0.79) and AAD incidence 6, 2, 4, 9, 1, 3